• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Hyperprolactinemia: Effective Treatment With Aripiprazole

Hyperprolactinemia: Effective Treatment With Aripiprazole

May 21, 2021
Christina Guest, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Christina Guest, MD Dr. Guest has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Zheng W et al, General Psychiatry 2019;32(5):e100091

Antipsychotic-induced hyperprolactinemia is a common adverse reaction contributing to treatment non-adherence. Male patients are embarrassed by the resulting breast enlargement, and female patients experience amenorrhea, infertility, and reduced bone density. We can bring prolactin levels down by decreasing the antipsychotic dose, switching to a different antipsychotic, or adding a dopamine agonist (eg, cabergoline), but these interventions put patients at risk of relapse.

Most antipsychotic medications cause hyperprolactinemia, though the risk is higher with first-generation agents and risperidone. Aripiprazole was the first antipsychotic approved with partial dopamine agonist activity, which may underlie its tendency to reduce, rather than raise, prolactin. Numerous case reports have found that adjunctive aripiprazole use reduces prolactin levels in antipsychotic-treated patients.

The authors conducted a meta-analysis of randomized controlled trials of patients with first-episode schizophrenia who received risperidone, olanzapine, or amisulpride (not approved as an antipsychotic in the US) with either adjunctive aripiprazole or placebo, and they compared patients’ serum prolactin levels. The final analysis included five randomized controlled trials with a total of 400 patients and a mean treatment duration of 11 weeks. A secondary outcome focused on improvement in psychosis as measured with the Positive and Negative Syndrome Scale (PANSS) or Brief Psychiatric Rating Scale (BPRS). The mean dose of aripiprazole was 7.5 mg/day (range 2.5–10 mg/day) in the four studies that included dosage.

Prolactin levels in patients receiving aripiprazole in addition to an antipsychotic were significantly lower, with a mean difference of 50 ng/mL. An additional benefit was that patients taking adjunctive aripiprazole experienced significant improvement in PANSS negative symptoms, though not in positive symptoms. The rate of side effects, including extrapyramidal side effects (EPS), in the patients on adjunctive aripiprazole was no higher than in the patients receiving placebo.

CHPR’s Take
Addition of a small to moderate dose of aripiprazole significantly lowers prolactin levels in patients with antipsychotic-induced hyperprolactinemia, without contributing to side effects including EPS. An added benefit is that negative symptoms may improve with this intervention. It remains to be seen if other newer antipsychotics with partial agonism activity (eg, brexpiprazole, cariprazine, lumateperone) will show similar effects.
Hospital Psychiatry
KEYWORDS aripiprazole prolactin
Christina Guest, MD

More from this author
www.thecarlatreport.com
Issue Date: May 21, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
Finally, Effective Treatments for Tardive Dyskinesia
Decisional Capacity
Capacity Assessment in Pregnant Patients
Suvorexant May Prevent Delirium in Hospitalized Patients
SSRIs and Intracerebral Hemorrhage Risk
Can Antidepressants Prolong Survival in Cancer Patients?
Hyperprolactinemia: Effective Treatment With Aripiprazole
Note From the Editor-in-Chief
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.